We have delivered 26 devices to Zealand University Hospital
OptoCeutics is pleased to announce the delivery of 26 devices to Zealand University Hospital for…
At Optoceutics, we are committed to developing disease-modifying digital therapeutics (DTx) for neurodegenerative and psychological disorders such as Alzheimer’s, MCI, ADHD, and depression.
We work at the intersection of neuroscience, engineering and artificial intelligence to create preventive health solutions that are safe, non-invasive and drug-free.
❚ Investigating Gamma Brain Waves for Alzheimer’s Disease
Optoceutics is currently conducting a clinical study to investigate the potential effect of masked 40 Hz flickering light on Alzheimer’s disease patients.
DISCLAIMER: All devices used in trials are considerd investigational devices and limited to investigational use only.
❚ Newsletter
Sign-up to our newsletter and receive new information about our developments, clinical trials and more.
❚ Selected Partners
❚ Latest News
We have started our clinical study for Alzheimer’s
Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System Recent studies in…
We are happy to announce our participation in the EU-funded Astrotech Project
This grant will enable OptoCeutics to hire two PhD candidates to conduct research in collaboration…
TV2 Lorry
TV2 Lorry has followed us for a long time in connection with our participation in…
Danish Tech Challenge Award Show
TV2 Lorry has followed us for a long time in connection with our participation in the Danish Tech Challenge.
